Holen Sie sich die Stockscreener-App
17.08
1.91%
0.32
Schlusskurs vom Vortag:
$16.76
Offen:
$16.69
24-Stunden-Volumen:
7,853
Relative Volume:
0.35
Marktkapitalisierung:
$90.74M
Einnahmen:
$858.00K
Nettoeinkommen (Verlust:
$-7.82M
KGV:
-11.78
EPS:
-1.4503
Netto-Cashflow:
$-27.59M
1W Leistung:
+2.77%
1M Leistung:
+0.83%
6M Leistung:
+102.61%
1J Leistung:
+317.32%
1-Tages-Spanne:
$16.69
$17.22
1-Wochen-Bereich:
$16.55
$17.24
52-Wochen-Spanne:
$3.6701
$17.57
Rallybio Corp Stock (RLYB) Company Profile
Firmenname
Rallybio Corp
Sektor
Branche
Telefon
203- 859-3820
Adresse
234 CHURCH STREET, NEW HAVEN
Compare RLYB vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
17.08 | 88.30M | 858.00K | -7.82M | -27.59M | -1.4503 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-05-15 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-02-07 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-04-10 | Eingeleitet | Wedbush | Outperform |
| 2022-12-09 | Eingeleitet | JP Morgan | Overweight |
| 2022-02-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-08-23 | Eingeleitet | Cowen | Outperform |
| 2021-08-23 | Eingeleitet | Evercore ISI | Outperform |
| 2021-08-23 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Rallybio Corp Aktie (RLYB) Neueste Nachrichten
Form 4 Rallybio Corp For: 28 September By Investing.com - Investing.com South Africa
Rallybio (NASDAQ: RLYB) holders expected to own 2.8% of new Avenzo - Stock Titan
Rallybio (NASDAQ: RLYB) Announces CFO Jonathan Lieber's Shift to Part-Time Role Starting September 15, 2026 - Kalkine Media
Rallybio's Jonathan Lieber to Shift to Part-Time CFO Role - TradingView
Rallybio Corp (NASDAQ: RLYB) Stock Price, News & Analysis - Kalkine
RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own? - Stocktwits
Rallybio Corp (RLYB) Debt 2025 - Stock Titan
Balyasny Asset Management L.P. Exits Rallybio Corp (RLYB) Stake in 13DG Filing - GuruFocus
Rallybio (RLYB) Holds Near $17 Ceiling as Traders Weigh Breakout PotentialWave Extension - vinanet.vn
Rallybio Company Profile & Introduction - Moomoo
Rallybio (NASDAQ:RLYB) Upgraded at Wall Street Zen - MarketBeat
Rallybio Corporation (RLYB) holders report 3.56% stake in Schedule 13G/A - Stock Titan
Cormorant Asset Management (RLYB) now reports 0% beneficial ownership of Rallybio - Stock Titan
RLYB Q1 2026 Earnings: Wider-than-Expected Loss Underscores Cost of Advancing Rare-Disease PipelineEBITDA Estimate Trend - vinanet.vn
Rallybio Corporation (NASDAQ:RLYB) Sees Large Drop in Short Interest - MarketBeat
Rallybio Corp (RLYB) sees Balyasny group report 0% ownership in 13G/A - Stock Titan
RLYB Q1 2026 Earnings: Wider Loss Highlights Acceleration of Clinical-Spend Run-RateGuidance vs Actual - vinanet.vn
Rallybio Corp (RLYB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rallybio (NASDAQ:RLYB) Releases Earnings Results, Beats Estimates By $8.81 EPS - MarketBeat
Rallybio Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
FMR LLC reports 15% Rallybio Corp (RLYB) stake, including 5% fund holding - Stock Titan
Rallybio Corp 2Q 2026: Revenue $0 Net income $43.67M, EPS $7.53— 10-Q Summary - TradingView
Laurion Capital exits Rallybio (RLYB) position, reports 0% beneficial ownership - Stock Titan
Rallybio Corp (RLYB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rallybio Q1 2026 Earnings: Wider-than-Expected Loss as Development Costs PersistGeographic Revenue Trends - dars.gov.et
RLYB|Rallybio Corp|Price:16.350|Chg%:+0.160 - TradingKey
Rallybio Corp (RLYB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rallybio Corp (RLYB) Balance Sheet - TradingKey
Rallybio Corp (RLYB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rallybio Corp (RLYB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rallybio Corporation (NASDAQ:RLYB) Sees Significant Decline in Short Interest - MarketBeat
RLYB|Rallybio Corp|Price:16.160|Chg%:-0.150 - TradingKey
Rallybio Market Sentiment - Benzinga España
Rallybio Corp (RLYB) Institutional Confidence - TradingKey
Rallybio Corp (RLYB) Financial Health: Profitability & Balance Sheet Analysis - tradingkey.com
Rallybio Corporation Revenue Breakdown – FWB:33M0 - TradingView
RLYB Q1 2026 Earnings: Wider-Than-Anticipated Loss as Biotech Continues Clinical InvestmentLong-Term Guidance - vinanet.vn
Rallybio Corporation Revenue Breakdown – TRADEGATE:33M0 - TradingView
Rallybio Corporation (RLYB) Surges 4%: Testing Resistance After Strong Upward MoveIV Contraction - vinanet.vn
Rallybio (RLYB) Gains Momentum After 2.88% Rally, Approaches Key ResistanceImpulse Wave - vinanet.vn
Rallybio Corporation (NASDAQ: RLYB) to merge and rebrand as Avenzo Therapeutics - Stock Titan
Total assets of Rallybio Corporation – FWB:33M0 - TradingView
Price to earnings forward of Rallybio Corporation – NASDAQ:RLYB - TradingView
Enterprise value to revenue forward of Rallybio Corporation – NASDAQ:RLYB - TradingView
Book value per share of Rallybio Corporation – FWB:33M0 - TradingView
Price to book forward of Rallybio Corporation – FWB:33M0 - TradingView
Long term debt to total equity ratio of Rallybio Corporation – FWB:33M0 - TradingView
Price to sales forward of Rallybio Corporation – FWB:33M0 - TradingView
Enterprise value to EBITDA forward of Rallybio Corporation – FWB:33M0 - TradingView
Net income before discontinued operations of Rallybio Corporation – FWB:33M0 - TradingView
Rallybio Corporation (RLYB) Edges Lower Amid Consolidation Near SupportPercent Below MA - dars.gov.et
Finanzdaten der Rallybio Corp-Aktie (RLYB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rallybio Corp-Aktie (RLYB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Liu Hui | Director |
Sep 24 '26 |
Option Exercise |
6.06 |
12,044 |
72,941 |
12,044 |
| Chung Wendy | Director |
Sep 16 '26 |
Option Exercise |
2.38 |
3,562 |
8,478 |
3,562 |
| Boudreau Helen M | Director |
Jul 06 '26 |
Option Exercise |
2.38 |
3,562 |
8,478 |
6,542 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 19 '26 |
Buy |
13.98 |
10,200 |
142,582 |
926,352 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 18 '26 |
Buy |
13.98 |
6,009 |
83,981 |
916,152 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 13 '26 |
Buy |
13.99 |
79,259 |
1,108,807 |
909,843 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 15 '26 |
Buy |
13.90 |
300 |
4,170 |
910,143 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 11 '26 |
Buy |
14.00 |
50,000 |
699,992 |
829,784 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 12 '26 |
Buy |
13.83 |
800 |
11,063 |
830,584 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 04 '26 |
Buy |
13.97 |
120,804 |
1,687,409 |
744,683 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):